Clinical Trials

19 enrolled 21 charts

Gynecologic

Ovarian Neoplasms, Peritoneal Neoplasms

NCT01346540 2025-02-12

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

16 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT02300298 2025-02-11

Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy

10 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT02182219 2025-01-22

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

21 enrolled

Genitourinary

Prostatic Neoplasms

NCT02668393 2021-01-29

Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

14 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT00805194 2018-12-05

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

1,314 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT01022853 2018-07-30

Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

30 enrolled 24 charts

Neoplasms

NCT00801294 2017-12-29

A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer

46 enrolled

Colorectal Neoplasms

NCT02182063 2017-12-28

A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer

81 enrolled

Genitourinary

Prostatic Neoplasms

NCT01015118 2017-12-07

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

1,366 enrolled 17 charts

Gynecologic

Ovarian Neoplasms, Peritoneal Neoplasms

NCT01004003 2017-10-26

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

125 enrolled 19 charts

Carcinoma, Hepatocellular

NCT02149108 2017-07-21

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

768 enrolled 10 charts

Colorectal Neoplasms

NCT00806819 2017-02-02

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

718 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT00710762 2016-08-15

A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer

89 enrolled 10 charts

Gynecologic

Ovarian Neoplasms

NCT00987935 2016-03-10

A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients

134 enrolled 29 charts

Carcinoma, Hepatocellular

NCT01594125 2016-02-12

Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma

30 enrolled 12 charts

Carcinoma, Hepatocellular

NCT00904839 2015-02-04

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

128 enrolled 21 charts

Colorectal Neoplasms

NCT00706628 2015-01-15

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

87 enrolled 20 charts

Genitourinary

Prostatic Neoplasms

NCT00715403 2014-12-02

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

41 enrolled 24 charts

Neoplasms

NCT02182102 2014-07-18

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

26 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02182128 2014-07-18

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

24 enrolled

Neoplasms

NCT02182206 2014-07-18

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

50 enrolled

Neoplasms

NCT01951846 2013-09-27

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

61 enrolled

Other solid neoplasm

Malignant Solid Tumour

NCT00730821 2009-08-21

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

28 enrolled